Found 70 matching trials
Bioavailability of Infacort When Administered Onto Food Compared to Direct Oral Administration PHASE1 This is a single centre, open-label, randomised, single dose, three-period,...
Show More Location
Simbec Research Ltd.
Learn More & Join Trial
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome PHASE2 This is an open-label extension study to evaluate the long-term safety of r...
Show More Status
Active Not Recruiting
Learn More & Join Trial
A Study to Assess the Effects of Repeat Doses of Fluticasone Furoate and GW642444M Combination in Healthy Subjects and in Subjects With Severe Impairment. PHASE1 This study will assess the saftey of giving fluticasone furoate 200mcg/GW64...
Show More Location
GSK Investigational Site
Learn More & Join Trial
A Study to Assess the Effects of Fluticasone Furoate and GW642444M Combination in Healthy Subjects and in Subjects With Mild, Moderate or Severe Hepatic Impairment. PHASE1 In relation to their severity, hepatic diseases can significantly modify dr...
Show More Location
GSK Investigational Site
Learn More & Join Trial
Long-term Safety Study of Chronocort in the Treatment of Participants With Congenital Adrenal Hyperplasia PHASE3 This phase III study is an open-label extension study to be conducted at ap...
Show More Location
Neurocrine Investigational Site in California
Learn More & Join Trial
An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome PHASE3 Participants in study C-1073-400 (NCT00569582) will be invited to participa...
Show More Location
University of Alabama at Birmingham School of Medicine
Learn More & Join Trial
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) PHASE3 This is a phase 3, randomized, open-label study of opevesostat compared to ...
Show More Location
University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0040)
Learn More & Join Trial
A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome PHASE3 Patients will receive Corlux (mifepristone) daily for up to 24 weeks. Asses...
Show More Location
University of Alabama at Birmingham School of Medicine
Learn More & Join Trial
ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016 PHASE2 To evaluate the outcome of a prednisolone and low dose methotrexate based p...
Show More Status
Active Not Recruiting
Location
Prince of Wales Hospital
Learn More & Join Trial
Hemodynamic Response to Angiotensin-II When Used as the Second Vasopressor Agent for Septic Shock PHASE4 Norepinephrine is a catecholamine that is the first-line vasopressor for se...
Show More Location
Kingman Regional Medical Center
Learn More & Join Trial